AZ forges ever-closer ties with China's CSPC Pharma
AstraZeneca has returned to China's CSPC Pharma to fill its R&D pipeline, reaching a new $1.77bn agreement to develop drugs for kidney diseases.
Newsletters and Deep Dive digital magazine
AstraZeneca has returned to China's CSPC Pharma to fill its R&D pipeline, reaching a new $1.77bn agreement to develop drugs for kidney diseases.
Find out more about Sam Dixey, Head of Medical Affairs Innovation and Technology (MAIT) at LUCENT Biopharma.
The digital, supplier, CRO, and medtech services sectors continued to see a steady flow of leadership changes during the month of May.
Rolling out new systems is usually not the hardest part. The bigger shift lies in how engagement is structured and executed.
Anthropic had made a big life sciences play with the launch of Claude Science, an AI 'workbench' for researchers involved in drug discovery.
Editor's Picks
Newsletters and Deep Dive
digital magazine